- Trial phase
- Approved
- Time to market
- Already approved and marketed since 1998.
- Why 3/10
- Enbrel has been FDA-approved since 1998 with no pending PDUFA, pivotal readout, or regulatory decision. It is a mature, declining product for Pfizer (a small part of a $60B+ portfolio). No hard binary catalyst is scheduled in the next 12 months, so the impact score cannot exceed 5.
Enbrel is a mature, declining asset for Pfizer with no upcoming binary catalysts. The key events to watch are the 2028-2029 US biosimilar entry window (Eticovo/Erelzi) and continued erosion of international sales, but neither is a near-term catalyst for PFE stock given Enbrel's small contribution to Pfizer's $60B+ revenue base.
Price Chart
Executive Summary
Enbrel (etanercept) is a long-approved TNF-inhibitor biologic for autoimmune diseases, originally developed by Immunex and now owned by Amgen (AMGN) in North America. Pfizer (PFE) holds international marketing rights outside the US and Canada through its 2009 Wyeth acquisition. The drug faces structural headwinds: Medicare price negotiation cut its US price by 67% effective January 2026, biosimilars have already crushed international sales, and two FDA-approved US biosimilars (Erelzi and Eticovo) await patent expirations in 2028-2029 to launch. For Pfizer, Enbrel is a legacy product with declining revenue and negligible impact on the company's $60B+ total revenue base.
How It Works
Enbrel is a biologic drug (a protein made from living cells) that acts as a TNF inhibitor. Tumor necrosis factor (TNF) is a naturally occurring protein in the body that drives inflammation in autoimmune diseases. Enbrel works by acting as a decoy receptor: it binds to TNF molecules in the bloodstream and prevents them from attaching to cells, thereby reducing the inflammatory response that causes joint swelling, pain, and skin plaques in conditions like rheumatoid arthritis and psoriasis.
Trial Status
Enbrel has been FDA-approved since November 1998 for five indications: rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a mature, commercially marketed biologic with no active pivotal trials for new indications.
The Two-Sided Case
Upcoming Catalysts
- No near-term regulatory catalysts for Enbrel itself. Key events to watch: (1) Resolution of Amgen's patent litigation with Sandoz/Samsung Bioepis determining US biosimilar entry timing (currently expected 2028-2029), (2) Continued sales erosion under Medicare's Maximum Fair Price of $2,355/month, (3) Teva's planned US commercialization of Eticovo biosimilar once patents allow.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report